Bank of New York Mellon Corp Purchases 2,301 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Bank of New York Mellon Corp grew its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 0.6% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 364,306 shares of the company’s stock after buying an additional 2,301 shares during the quarter. Bank of New York Mellon Corp’s holdings in Intellia Therapeutics were worth $8,153,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in NTLA. Vanguard Group Inc. raised its holdings in shares of Intellia Therapeutics by 8.9% in the first quarter. Vanguard Group Inc. now owns 9,093,712 shares of the company’s stock valued at $250,168,000 after acquiring an additional 746,263 shares in the last quarter. Norges Bank bought a new stake in shares of Intellia Therapeutics in the 4th quarter valued at about $16,348,000. Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in shares of Intellia Therapeutics in the 4th quarter worth approximately $9,086,000. Pinnacle Associates Ltd. bought a new position in shares of Intellia Therapeutics during the first quarter valued at approximately $7,035,000. Finally, Opaleye Management Inc. increased its holdings in Intellia Therapeutics by 157.6% during the first quarter. Opaleye Management Inc. now owns 255,000 shares of the company’s stock valued at $7,015,000 after buying an additional 156,000 shares during the period. Institutional investors own 88.77% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have weighed in on NTLA. Evercore ISI upgraded Intellia Therapeutics to a “strong-buy” rating in a report on Friday, August 9th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $65.00 price objective on shares of Intellia Therapeutics in a research report on Monday, June 24th. JPMorgan Chase & Co. reduced their target price on shares of Intellia Therapeutics from $61.00 to $55.00 and set an “overweight” rating for the company in a report on Monday, August 12th. Truist Financial restated a “buy” rating and issued a $120.00 price target on shares of Intellia Therapeutics in a report on Monday, June 24th. Finally, StockNews.com raised shares of Intellia Therapeutics to a “sell” rating in a research report on Thursday, June 27th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Intellia Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $61.58.

Intellia Therapeutics Trading Up 1.5 %

NASDAQ:NTLA opened at $20.12 on Wednesday. Intellia Therapeutics, Inc. has a twelve month low of $19.31 and a twelve month high of $38.71. The company has a market cap of $2.04 billion, a PE ratio of -3.75 and a beta of 1.77. The company’s 50 day moving average is $23.57 and its two-hundred day moving average is $24.65.

Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($1.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.29). The firm had revenue of $7.00 million for the quarter, compared to analysts’ expectations of $19.68 million. Intellia Therapeutics’s revenue was down 48.5% on a year-over-year basis. During the same quarter in the previous year, the business earned ($1.40) earnings per share. As a group, analysts expect that Intellia Therapeutics, Inc. will post -5.19 EPS for the current fiscal year.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.